HeraMED Ltd. (AU:HMD)
ASX:HMD
Top Page
HeraMED Ltd.
(Sydney:HMD)
Select Model
Select Model
Rating:54Neutral
Price Target:
AU$0.05
▲(27.50% Upside)
Action:ReiteratedDate:03/31/26
The score is held back primarily by weak financial performance—persistent losses and recurring negative operating/free cash flow—despite improved gross margin and a cleaner balance sheet. Technicals are a notable positive with the price above all key moving averages and positive momentum indicators. Valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Niche digital women's health focus
HeraMED's explicit focus on pregnancy and maternal remote monitoring is a durable strategic position. The company's software and connected-care capabilities (data capture and clinical decision support) align with long-term structural trends toward telehealth, enabling sustained customer stickiness and differentiated product-market fit if adoption grows.
Negative Factors
Persistent negative operating and free cash flow
Operating and free cash flow have been negative each year, creating ongoing funding needs. Persistent cash burn increases reliance on external financing, risks dilution, and limits the company's ability to invest in sales, marketing, or product development required to scale revenues and realize margin potential over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche digital women's health focus
HeraMED's explicit focus on pregnancy and maternal remote monitoring is a durable strategic position. The company's software and connected-care capabilities (data capture and clinical decision support) align with long-term structural trends toward telehealth, enabling sustained customer stickiness and differentiated product-market fit if adoption grows.
Read all positive factors
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$55.81M
Dividend YieldN/A
Average Volume (3M)1.96M
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue Growth-34.06%
EPS Growth75.47%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,116,287,200
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)27.61
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HeraMED Ltd. Business Overview & Revenue Model
Company Description
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate...
How the Company Makes Money
null...
HeraMED Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 195.77K | 225.49K | 413.19K | 215.81K | 83.68K |
| Gross Profit | 99.78K | 135.29K | 248.12K | -214.69K | -219.50K |
| EBITDA | -2.56M | -3.35M | -3.97M | -3.17M | -3.93M |
| Net Income | ― | -3.40M | -4.50M | -4.88M | -5.71M |
Balance Sheet | |||||
| Total Assets | 994.94K | 2.78M | 2.01M | 4.19M | 4.57M |
| Cash, Cash Equivalents and Short-Term Investments | 914.65K | 3.13M | 723.29K | 2.64M | 3.55M |
| Total Debt | 282.39K | 815.96K | 209.37K | 179.53K | 3.41M |
| Total Liabilities | 559.96K | 1.06M | 1.55M | 1.30M | 4.13M |
| Stockholders Equity | 931.03K | 1.72M | 466.70K | 2.88M | -105.66K |
Cash Flow | |||||
| Free Cash Flow | -2.44M | -2.98M | -5.57M | -3.20M | -3.20M |
| Operating Cash Flow | -2.44M | -2.98M | -5.57M | -2.52M | -3.12M |
| Investing Cash Flow | 0.00 | 0.00 | -2.05K | -690.78K | -85.43K |
| Financing Cash Flow | 1.27M | 6.88M | 2.96M | 2.54M | 4.88M |
HeraMED Ltd. Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.04
Positive
0.03
Positive
Market Momentum
<0.01
Negative
65.46
Neutral
68.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HMD, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.46 is Neutral, neither overbought nor oversold. The STOCH value of 68.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HMD.
HeraMED Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$55.81M | -9.32 | -417.72% | ― | -34.06% | 75.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$22.66M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
43 Neutral | AU$3.12M | -0.88 | -358.43% | ― | -30.80% | -38.95% | |
41 Neutral | AU$13.43M | -0.50 | 459.94% | ― | -2.82% | 32.47% | |
40 Underperform | AU$27.55M | -4.09 | -58.40% | ― | -7.20% | 28.70% |
* Healthcare Sector Average
AU:HMD
HeraMED Ltd.
0.05
0.03
177.78%
AU:UCM
Uscom Limited
0.01
-0.02
-58.62%
AU:AT1
Atomo Diagnostics Ltd.
0.03
0.01
70.00%
AU:ADR
Adherium Ltd.
0.01
0.00
0.00%
AU:CBL
Control Bionics Ltd.
0.06
<0.01
10.00%
HeraMED Ltd. Corporate Events
HeraMED Issues 38.7 Million New Shares Under Cleansing Notice
Apr 2, 2026
HeraMED Limited has issued 38,699,315 new fully paid ordinary shares on 2 April 2026, relying on provisions that allow the placement without a formal prospectus-style disclosure to investors. The move expands the company’s share base and may...
HeraMED Seeks ASX Quotation for 38.7 Million New Shares
Apr 1, 2026
HeraMED Ltd. has applied to the ASX for quotation of 38,699,315 new fully paid ordinary shares under the ticker HMD. The securities form part of a transaction previously notified to the market, with the new shares issued on 2 April 2026.The move w...
HeraMED Sets May 2026 AGM Date and Deadline for Director Nominations
Mar 30, 2026
HeraMED Limited has scheduled its Annual General Meeting for 21 May 2026 at 9:00am AEST, and has set 9 April 2026 as the deadline for shareholders or other eligible parties to submit director nominations. The timing formalises the company’s ...
HeraMED Wins Near-Unanimous Shareholder Backing at Extraordinary General Meeting
Mar 26, 2026
HeraMED Limited reported that shareholders overwhelmingly approved all resolutions put to an Extraordinary General Meeting held on 26 March 2026 in Melbourne. The passed resolutions included ratifications of prior share and option issues, approval...
HeraMED Director Converts Performance Rights Into Ordinary Shares
Mar 16, 2026
HeraMED Ltd. has disclosed a change in director Anoushka Gungadin’s interests following the vesting and exercise of performance rights into ordinary shares. The update reflects a routine equity conversion that alters the mix of her holdings ...
HeraMED Issues 2.63 Million New Shares Under Cleansing Notice
Mar 11, 2026
HeraMED Limited has issued 2,633,860 new fully paid ordinary shares on 12 March 2026, using provisions that allow issuance without a full disclosure document under the Corporations Act. The company states it is fully compliant with financial repor...
HeraMED Seeks ASX Quotation for 2.63 Million New Shares
Mar 11, 2026
HeraMED Ltd. has applied to the ASX for quotation of 2,633,860 new ordinary fully paid shares under the ticker HMD. The securities, issued on 12 March 2026 following the exercise or conversion of existing options or other convertible instruments, ...
HeraMED Files Updated Corporate Governance Statement with ASX
Feb 27, 2026
HeraMED Ltd has lodged its updated corporate governance statement for the year ended 31 December 2025, confirming compliance with ASX Listing Rules that require disclosure of how it adheres to the ASX Corporate Governance Council’s recommend...
HeraMED Narrows Annual Loss Despite Revenue Decline and Weaker Asset Base
Feb 27, 2026
HeraMED Limited has reported a 10.3% decline in revenues from ordinary activities to $431,605 for the year ended 31 December 2025, while its net loss after tax narrowed by 24.8% to $4.13 million compared with the prior year. The company did not de...
HeraMED Highlights AI-Driven Women’s Health Strategy in Investor Presentation
Feb 26, 2026
HeraMED has released an investor presentation outlining its position as a leader in AI-enabled women’s health, leveraging an FDA-cleared device to deliver solutions from pregnancy through to chronic care. The update is intended to inform inv...
HeraMED Calls March EGM and Urges Shift to Digital Shareholder Communications
Feb 23, 2026
HeraMED Limited has called an Extraordinary General Meeting for 26 March 2026 in Hawthorn East, Victoria, and will provide the Notice of Meeting primarily via electronic distribution in line with updated provisions of the Corporations Act. The com...
HeraMED appoints U.S. healthcare leader Adam Myers to spearhead HeraCARE’s U.S. expansion
Feb 9, 2026
HeraMED has appointed U.S. healthcare leader Dr Adam Myers as Chairman of its Commercial Scientific Advisory Board, adding significant clinical and executive expertise from major health systems, payer organisations and digital health enterprises t...
HeraMED Seeks ASX Quotation for 2.15 Million New Shares
Feb 3, 2026
HeraMED Limited has applied to the ASX for quotation of 2,150,000 new fully paid ordinary shares under its issuer code HMD, with an issue date of 4 February 2026. The additional securities, arising from the exercise or conversion of existing optio...
HeraMED Issues 41.3 Million New Shares, Confirms Regulatory Compliance
Feb 3, 2026
HeraMED Limited has issued 41,300,685 fully paid ordinary shares on 4 February 2026, in line with a prior capital-related announcement and a corresponding Appendix 2A filing. The company confirmed the new shares were issued without a prospectus un...
HeraMED Seeks ASX Quotation for 41.3 Million New Shares
Feb 3, 2026
HeraMED Limited has applied to the ASX for quotation of 41,300,685 new fully paid ordinary shares, to be traded under its existing code HMD. The issuance, tied to previously announced transactions, will expand the company’s quoted share base...
HeraMED Secures Key US Deals and Regulatory Milestone as Maternity Tech Push Gains Pace
Jan 30, 2026
HeraMED reported a pivotal December 2025 quarter as it accelerated its US push through two significant commercial agreements: a deal with Philips’ US subsidiary to jointly offer an integrated digital maternity care solution to American hospi...
HeraMED Raises A$3.2m to Accelerate Global Rollout of Digital Maternity Platform
Jan 27, 2026
HeraMED Limited has secured firm commitments to raise A$3.2 million through a two‑tranche placement of 80 million new shares at A$0.04 each, a roughly 7% discount to its last closing price, with support from new institutional and sophisticat...
HeraMED Shares Halted Pending Material Capital Raising Announcement
Jan 21, 2026
HeraMED Ltd has requested and been granted a trading halt on its ordinary shares on the Australian Securities Exchange, effective 22 January 2026, while it prepares a market announcement regarding a material proposed capital raising. The halt, whi...
HeraMED Switches Auditor and Adds Joint Company Secretary to Bolster Governance
Jan 5, 2026
HeraMED Limited has appointed William Buck Audit (Vic) Pty Ltd as its new external auditor following the resignation of BDO Audit Pty Ltd, after a competitive tender process, with the appointment to be put to shareholders for ratification at the c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.